Tiziana Life Sciences plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Tiziana Life Sciences plc
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
- Large Molecule
- Other Names / Subsidiaries
- LonGevia Genomics Srl
- Shardna SpA
- Tiziana Group
- Tiziana Life Sciences Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.